These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 26045064)

  • 21. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Butyrylcholinesterase level as an independent factor of erythropoiesis-stimulating agent resistance in patients on maintenance hemodialysis: a single-center cross-sectional study.
    Okamoto T; Hatakeyama S; Tanaka Y; Imanishi K; Takashima T; Saitoh F; Koie T; Suzuki T; Ohyama C
    Clin Exp Nephrol; 2018 Oct; 22(5):1174-1181. PubMed ID: 29600410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.
    Majoni SW; Ellis JA; Hall H; Abeyaratne A; Lawton PD
    Hemodial Int; 2014 Oct; 18(4):740-50. PubMed ID: 24766376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
    Pergola PE; Devalaraja M; Fishbane S; Chonchol M; Mathur VS; Smith MT; Lo L; Herzog K; Kakkar R; Davidson MH
    J Am Soc Nephrol; 2021 Jan; 32(1):211-222. PubMed ID: 33272965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis.
    Handelman GJ; Walter MF; Adhikarla R; Gross J; Dallal GE; Levin NW; Blumberg JB
    Kidney Int; 2001 May; 59(5):1960-6. PubMed ID: 11318969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to Erythropoiesis-Stimulating Agents in Pre-Dialysis and Post-Dialysis Mortality in Japanese Incident Hemodialysis Patients.
    Hayashi T; Joki N; Tanaka Y; Iwasaki M; Kubo S; Matsukane A; Takahashi Y; Imamura Y; Hirahata K; Hase H
    Blood Purif; 2019; 47 Suppl 2(Suppl 1):31-37. PubMed ID: 30943479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial.
    Himmelfarb J; Ikizler TA; Ellis C; Wu P; Shintani A; Dalal S; Kaplan M; Chonchol M; Hakim RM
    J Am Soc Nephrol; 2014 Mar; 25(3):623-33. PubMed ID: 24371300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.
    Freburger JK; Ellis AR; Wang L; Butler AM; Kshirsagar AV; Winkelmayer WC; Brookhart MA
    Am J Kidney Dis; 2016 Feb; 67(2):271-82. PubMed ID: 26508682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationships among the Dosage of Erythropoiesis-Stimulating Agents, Erythropoietin Resistance Index, and Mortality in Maintenance Hemodialysis Patients.
    Pan S; Zhao DL; Li P; Sun XF; Zhou JH; Song KK; Wang Y; Miao LN; Ni ZH; Lin HL; Liu FY; Li Y; He YN; Wang NS; Wang CL; Zhang AH; Chen MH; Yang XP; Deng YY; Shao FM; Fu SX; Fang JA; Cai GY; Chen XM
    Blood Purif; 2022; 51(2):171-181. PubMed ID: 34175850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients.
    Luo J; Jensen DE; Maroni BJ; Brunelli SM
    Am J Kidney Dis; 2016 Nov; 68(5):763-771. PubMed ID: 27528373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study.
    Santos EJF; Hortegal EV; Serra HO; Lages JS; Salgado-Filho N; Dos Santos AM
    Braz J Med Biol Res; 2018; 51(7):e7288. PubMed ID: 29742267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between anti-erythropoietin receptor autoantibodies and responsiveness to erythropoiesis-stimulating agents in patients on hemodialysis: a multi-center cross-sectional study.
    Hara A; Koshino Y; Kurokawa Y; Shinozaki Y; Miyake T; Kitajima S; Toyama T; Iwata Y; Sakai N; Shimizu M; Furuichi K; Nakamura H; Wada T
    Clin Exp Nephrol; 2020 Jan; 24(1):88-95. PubMed ID: 31502102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients.
    Petrulienė K; Žiginskienė E; Kuzminskis V; Nedzelskienė I; Bumblytė IA
    Medicina (Kaunas); 2017; 53(2):90-100. PubMed ID: 28416170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus.
    Hasegawa T; Zhao J; Bieber B; Zee J; Pisoni RL; Robinson BM; Hanafusa N; Nangaku M
    Kidney Blood Press Res; 2021; 46(3):352-361. PubMed ID: 33887741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage.
    Kuragano T; Kitamura K; Matsumura O; Matsuda A; Hara T; Kiyomoto H; Murata T; Fujimoto S; Hase H; Joki N; Fukatsu A; Inoue T; Itakura Y; Nakanishi T
    PLoS One; 2016; 11(3):e0147328. PubMed ID: 26933949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized controlled trial evaluating the erythropoiesis stimulating agent sparing potential of a vitamin E-bonded polysulfone dialysis membrane.
    Lines SW; Carter AM; Dunn EJ; Lindley EJ; Tattersall JE; Wright MJ
    Nephrol Dial Transplant; 2014 Mar; 29(3):649-56. PubMed ID: 24293660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient.
    Goodkin DA; Zhao J; Cases A; Nangaku M; Karaboyas A
    Am J Nephrol; 2022; 53(5):333-342. PubMed ID: 35462377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis.
    Kiss Z; Ambrus C; Almasi C; Berta K; Deak G; Horonyi P; Kiss I; Lakatos P; Marton A; Molnar MZ; Nemeth Z; Szabo A; Mucsi I
    Nephron Clin Pract; 2011; 117(4):c373-8. PubMed ID: 21071961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Coenzyme Q
    Rivara MB; Yeung CK; Robinson-Cohen C; Phillips BR; Ruzinski J; Rock D; Linke L; Shen DD; Ikizler TA; Himmelfarb J
    Am J Kidney Dis; 2017 Mar; 69(3):389-399. PubMed ID: 27927588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.